Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Melasma treatment showdown: needle or pill?

NCT ID NCT07280234

Disease control Sponsor: Hayat Abad Medical Complex, Peshawar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in Pakistan compared two ways of giving tranexamic acid for melasma: tiny skin injections versus pills. 218 adults with melasma took part. Researchers measured changes in the Melasma Area and Severity Index after 8 weeks to see which method worked better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tranexamic acid
What this could lead to
If it works, this could point toward a more effective or convenient way to treat melasma, a common skin condition causing dark patches.
What could go wrong
This is a small, early-phase study (218 people) with no blinding or long-term follow-up. Results may not apply to all skin types or guarantee lasting improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

218 people

The number who actually took part.

Started

Nov 2024

Finished

May 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 18 to 55 years, with clinically confirmed melasma of at least 6 months duration. 2. Fitzpatrick skin types III-V and no active dermatological conditions in the treatment area. Exclusion Criteria: 1. pregnancy or lactation 2. History of thromboembolic disorders 3. Use of hormonal therapies or photosensitizing medications 4. Recent melasma treatments within the past 3 months 5. Known hypersensitivity to tranexamic acid.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma

Contacts and locations

Locations

  • MTI-HMC Peshawar, Peshawar Khyber Pakhtunkhwa

    Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.